BIIB — Biogen Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapSuper Stock

Annual cashflow statement for Biogen, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	1,728	2,962	1,162	1,632	1,293
Depreciation
Deferred Taxes
Non-Cash Items	1,997	-1,037	845	883	828
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-146	-890	-649	-155	-1,058
Change in Accounts Receivable
Change in Inventories
Change in Accrued Expenses
Change in Taxes Payable
Net Change in Other Assets & Liabilities
Cash from Operating Activities	3,640	1,384	1,547	2,876	2,205
Capital Expenditures	-295	-243	-311	-360	-185
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-269	1,820	-3,790	-439	-1,186
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-564	1,577	-4,101	-799	-1,371
Financing Cash Flow Items	-116	4.9	-38	-33.5	-285
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-2,086	-1,747	149	-684	-302
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	930	1,158	-2,369	1,325	634